VectorY Therapeutics has increased enrollment in its global Phase I/II PIONEER-ALS trial of VTx-002 from 12 to 36 participants across Europe, the UK and the US. The open-label, dose-escalation study will evaluate two dose levels and measure safety, PK/PD and exploratory biomarkers such as NfL and new TDP-43 pathway markers. The expansion aims to generate a broader dataset to better assess early biological signals that might translate to clinical benefit.
VectorY Expands PIONEER-ALS Phase I/II Trial to 36 Participants to Broaden TDP‑43 Data
ALS is a fatal neurodegenerative condition with no cure and limited treatment options for symptom management. Credit: Andrzej Rostek/Shutterstock.com.
VectorY Therapeutics has expanded its global Phase I/II PIONEER-ALS trial of VTx-002, increasing the cohort from 12 to 36 participants across sites in Europe, the United Kingdom and the United States.
Trial Design and Expansion
The open-label, dose-escalation, multicentre study is evaluating tolerability, safety, pharmacodynamic responses and pharmacokinetics of two dose levels of VTx-002 in people diagnosed with amyotrophic lateral sclerosis (ALS). Rapid recruitment and accelerated site activations enabled the company to triple enrollment to generate a broader early clinical dataset.
Clinical Progress
Dosing in the PIONEER-ALS study began with the first US participants in February 2026 at Massachusetts General Hospital's Sean M. Healey & AMG Center for ALS and later expanded to Europe in September at University Medical Center Utrecht.
About VTx-002
VTx-002 is an investigational, unapproved vectorised antibody engineered to target pathological accumulations of the TDP-43 protein, a hallmark observed in up to 97% of ALS cases. The therapy uses a vector delivery system intended to sustain antibody expression within the central nervous system over time.
Endpoints and Biomarkers
Beyond primary safety and pharmacology objectives, the trial will assess secondary and exploratory measures, including post-treatment Neurofilament light chain (NfL) trajectories and emerging biomarkers linked to the TDP-43 pathway. Clinical assessments include the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), slow vital capacity (SVC), hand-held dynamometry and survival outcomes.
Jim Scibetta, VectorY CEO, said that tripling the study population substantially increases the opportunity to leverage secondary and exploratory endpoints to gain a stronger preliminary understanding of whether VTx-002 is affecting the biological drivers of ALS in ways that could translate into clinical benefit and potential disease modification.
VectorY is advancing a broader neurodegenerative pipeline that includes VTx-003 for Huntington's disease, VTx-004 for frontotemporal dementia and VTx-005 for Alzheimer's disease.
Originally published by Clinical Trials Arena, a GlobalData brand.
Help us improve.
